ClinicalTrials.gg
CompletedNCT04858490Updated May 14, 2026Results posted

Remote Treatment of Alcohol Withdrawal

An interventional study of Diazepam in Alcohol Withdrawal, sponsored by Centre for Addiction and Mental Health. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Alcoholism by Centre for Addiction and Mental Health — 3 open to participants now, 4 under way, none of them phase 3. Alcoholism · Centre for Addiction and Mental Health.

Enrollment
17th of 22
30 · median 48
Started
2021
with 2 others
No phase
14 of 22
2 open now
Registered
13th of 22
by date

Among the 22 studies in Alcoholism by Centre for Addiction and Mental Health, this one is the 17th largest by enrollment, is one of 3 that started in 2021, is one of 14 with no phase, and was the 13th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

3 of the 22 studies in Alcoholism by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Alcoholism by Centre for Addiction and Mental Health, or all of them as a file.
02

Study summary

This study will evaluate the feasibility of delivering symptom-triggered alcohol withdrawal management by telemedicine and determine whether this intervention is satisfactory to patients.

Read the detailed description

This single-arm pilot feasibility study will recruit actively drinking participants with a history of alcohol withdrawal in order to provide remotely monitored symptom-triggered alcohol withdrawal treatment using telemedicine. Participants will initially complete a screening and eligibility visit. If eligible, participants will then be scheduled for 3-day remote withdrawal management (which can be extended by 1-2 days if medically indicated). During remote withdrawal management, participants will receive symptom-triggered diazepam treatment using a modified version of the Clinical Institute Withdrawal Assessment for Alcohol Scale, revised (CIWA-Ar). Within one week following termination of withdrawal treatment, participants will be scheduled for a remote follow up visit in which they will complete patient satisfaction questionnaires and will be offered weekly counselling sessions and anticraving medication to prevent relapse to alcohol use. Approximately 30 days following treatment initiation, relapse to alcohol use will be assessed.

03

Conditions studied

  • Alcohol Withdrawal

Browse trials for

Keywords

  • Withdrawal Management
  • Telemedicine
  • Alcohol Withdrawal
  • Alcohol Withdrawal Management
  • Alcohol Use Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years and older
  • Are actively using alcohol
  • Previously met , Fifth Edition (DSM-5) B criteria for alcohol withdrawal
  • Aim to achieve at least 30 days of abstinence as a treatment goal following initiation of remote alcohol withdrawal management
  • Are able to provide in English.
  • Reside or are able to stay at an address within 2-hours travelling distance from the Centre for Addiction and Mental Health for the entire duration of the remote withdrawal procedure
  • Are enrolled in the Ontario Health Insurance Plan (OHIP)

Exclusion criteria

Exclusion Criteria:

  • History of complicated withdrawal including withdrawal seizures, hallucinosis, or delirium
  • Positive UDS for sedatives or opioids, currently prescribed sedatives or opioids, or diagnosis of sedative-hypnotic or opioid use disorder within the past year (based on assessment). Individuals prescribed low doses of benzodiazepines (e.g. lorazepam 1mg PO daily) or with a positive urine benzodiazepine screen that is not thought to be due to benzodiazepine misuse may be permitted to proceed with the study at the discretion of the study physician.
  • Severe medical or psychiatric comorbidity that would prevent safe participation in the study
  • to the safe use of diazepam including: known to diazepam severe respiratory insufficiency, severe hepatic insufficiency, sleep apnea syndrome, acute narrow-angle glaucoma, and myasthenia gravis. Individuals with sleep apnea may be permitted to proceed with the study at the discretion of the study physician.
  • Active withdrawal symptoms (CIWA-Ar > 12) at the time of the eligibility assessment
  • Active suicidal ideation at the time of eligibility assessment
  • Positive urine pregnancy test, actively breastfeeding, or planning to become pregnant or breastfeed during the study period
  • Lack of stable housing
  • Enrollment in another study that conflicts with the procedures or scientific integrity of this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Symptom-triggered diazepam treatment

    Participants will be treated for a period of 3 days using a symptom-triggered withdrawal management protocol delivered over telemedicine. Participants who score 10 or above on the modified CIWA-Ar will be advised to take a specific dose of diazepam (either 10 or 20mg, at the clinician's discretion). Participants will be reassessed regularly over the 3-day period.

    Drug: Diazepam

Interventions

  • Symptom-triggered diazepam treatment: 10 or 20mg, at the clinician's discretion

    Also known as: Valium

06

What researchers measure

Primary outcomes

  1. Retention in Treatment

    Retention in treatment, as measured by the percentage of participants who complete the entire 3-day remote withdrawal management protocol.

    Time frame: 3-5 day treatment period

  2. Transfer to a Higher Level of Care

    Transfer to a higher level of care, as measured by the percentage of participants sent to the emergency room due to complications, need for intensive monitoring, or acute intoxication. If ≤ 20%, of participants require transfer to a higher level of care, we will consider this as additional evidence of feasibility.

    Time frame: 3-5 day treatment period

Secondary outcomes

  1. Patient Satisfaction With the Treatment Protocol

    Satisfaction with the overall treatment protocol, measured with the Client Satisfaction Questionnaire-8 (minimum score = 8; maximum score = 32; higher score indicates greater client satisfaction).

    Time frame: Measured within 1 week of completing the remote withdrawal procedure

  2. Patient Satisfaction With the Telemedicine Platform

    Satisfaction with the telemedicine platform, measured with a modified version of the Telehealth Satisfaction Scale (minimum score = 12; maximum score = 48; higher score indicates greater satisfaction with the telemedicine platform).

    Time frame: Measured within 1 week of completing the remote withdrawal procedure

  3. Duration of Active Withdrawal Treatment

    Duration of active withdrawal treatment, as measured by the number of days that patients received diazepam among patients who received benzodiazepines.

    Time frame: 3-5 day treatment period

  4. Requirement of Benzodiazepines

    Benzodiazepines requirement, as measured by the percentage of participants requiring benzodiazepine treatment.

    Time frame: 3-5 day treatment period

  5. Diazepam Dose

    Diazepam dose, as measured by the average dose of diazepam required to control symptoms among patients who received diazepam.

    Time frame: 3-5 day treatment period

  6. Withdrawal Severity

    Withdrawal severity, as measured by the average peak Clinical Institute Withdrawal Assessment for Alcohol Scale, revised score measured over the treatment period (minimum score = 0; maximum score = 67; higher score indicates greater withdrawal severity).

    Time frame: 3-5 day treatment period

07

Results

Posted May 14, 2026

Participant flow

Participant flow — Overall Study
MilestoneSymptom-triggered Diazepam Treatment
Started30
Completed28
Not completed2
Withdrew: Relapse to alcohol during treatment2

Outcome measures

PrimaryRetention in Treatment

Retention in treatment, as measured by the percentage of participants who complete the entire 3-day remote withdrawal management protocol.

Time frame:
3-5 day treatment period
Reported as:
Count of participants · Participants
Retention in Treatment
ParticipantsSymptom-triggered Diazepam Treatment
Retention in Treatment28
Statistical analysis
  • Symptom-triggered Diazepam Treatment · Exact binomial test · p = 0.0021
PrimaryTransfer to a Higher Level of Care

Transfer to a higher level of care, as measured by the percentage of participants sent to the emergency room due to complications, need for intensive monitoring, or acute intoxication. If ≤ 20%, of participants require transfer to a higher level of care, we will consider this as additional evidence of feasibility.

Time frame:
3-5 day treatment period
Reported as:
Count of participants · Participants
Transfer to a Higher Level of Care
ParticipantsSymptom-triggered Diazepam Treatment
Transfer to a Higher Level of Care0
Statistical analysis
  • Symptom-triggered Diazepam Treatment · Exact binomial test · p = 0.0012
SecondaryPatient Satisfaction With the Treatment Protocol

Satisfaction with the overall treatment protocol, measured with the Client Satisfaction Questionnaire-8 (minimum score = 8; maximum score = 32; higher score indicates greater client satisfaction).

Time frame:
Measured within 1 week of completing the remote withdrawal procedure
Reported as:
Mean · Score on a scale
Patient Satisfaction With the Treatment Protocol
Score on a scaleSymptom-triggered Diazepam Treatment
Patient Satisfaction With the Treatment Protocol30.9 ± 1.5
SecondaryPatient Satisfaction With the Telemedicine Platform

Satisfaction with the telemedicine platform, measured with a modified version of the Telehealth Satisfaction Scale (minimum score = 12; maximum score = 48; higher score indicates greater satisfaction with the telemedicine platform).

Time frame:
Measured within 1 week of completing the remote withdrawal procedure
Reported as:
Mean · Score on a scale
Patient Satisfaction With the Telemedicine Platform
Score on a scaleSymptom-triggered Diazepam Treatment
Patient Satisfaction With the Telemedicine Platform45.1 ± 2.5
SecondaryDuration of Active Withdrawal Treatment

Duration of active withdrawal treatment, as measured by the number of days that patients received diazepam among patients who received benzodiazepines.

Time frame:
3-5 day treatment period
Reported as:
Mean · days
Duration of Active Withdrawal Treatment
daysSymptom-triggered Diazepam Treatment
Duration of Active Withdrawal Treatment2.4 ± 0.7
SecondaryRequirement of Benzodiazepines

Benzodiazepines requirement, as measured by the percentage of participants requiring benzodiazepine treatment.

Time frame:
3-5 day treatment period
Reported as:
Count of participants · Participants
Requirement of Benzodiazepines
ParticipantsSymptom-triggered Diazepam Treatment
Requirement of Benzodiazepines27
SecondaryDiazepam Dose

Diazepam dose, as measured by the average dose of diazepam required to control symptoms among patients who received diazepam.

Time frame:
3-5 day treatment period
Reported as:
Median · mg
Diazepam Dose
mgSymptom-triggered Diazepam Treatment
Day 130 (10 to 50)
Day 220 (0 to 40)
Day 310 (0 to 20)
SecondaryWithdrawal Severity

Withdrawal severity, as measured by the average peak Clinical Institute Withdrawal Assessment for Alcohol Scale, revised score measured over the treatment period (minimum score = 0; maximum score = 67; higher score indicates greater withdrawal severity).

Time frame:
3-5 day treatment period
Reported as:
Mean · score on a scale
Withdrawal Severity
score on a scaleSymptom-triggered Diazepam Treatment
Day 112.1 ± 4.3
Day 29.4 ± 4.7
Day 36.6 ± 4.2

Adverse events

Collected over The adverse events reported were collected throughout the withdrawal treatment phase of the study (Detox day 1-3). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symptom-triggered Diazepam Treatment0/30 (0%)0/30 (0%)22/30 (73.3%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSymptom-triggered Diazepam Treatment
SedationNervous system disorders19/30
ClumsinessNervous system disorders5/30
Memory LossNervous system disorders3/30
Light-headednessNervous system disorders3/30
DizzinessNervous system disorders3/30
Leg WeaknessMusculoskeletal and connective tissue disorders3/30
HypertensionCardiac disorders1/30
ConfusionNervous system disorders0/30
FallsNervous system disorders0/30
SeizuresNervous system disorders0/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Symptom-triggered Diazepam Treatment
Mean44.0 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Symptom-triggered Diazepam Treatment
Female12
Male18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Symptom-triggered Diazepam Treatment
Ethnicity — White-European20
Ethnicity — Other10
Marital Status
Marital Status(Participants)Symptom-triggered Diazepam Treatment
Married/Common Law12
Other18
Income
Income(Participants)Symptom-triggered Diazepam Treatment
> $60 00015
< $60,00015
Education
Education(Participants)Symptom-triggered Diazepam Treatment
Higher Education Past Secondary School24
Other6
Prior Detoxification Experience
Prior Detoxification Experience(Participants)Symptom-triggered Diazepam Treatment
Yes13
No17
Alcohol Use Disorders Identification Test (AUDIT)
Alcohol Use Disorders Identification Test (AUDIT)(units on a scale)Symptom-triggered Diazepam Treatment
Mean29.9 ± 4.2

5 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Centre for Addiction and Mental Health
    Toronto, Ontario M6J 1H4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2023, 24 months.

Results were first posted in May 2026, 2 years 6 months after primary completion.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 24 months is below that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2021
First posted
Apr 26, 2021
StartActual
Sep 24, 2021
Primary completionActual
Oct 16, 2023
CompletionActual
Nov 21, 2023
Results first posted
May 14, 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04858490
Collaborators
Ontario Ministry of Health and Long Term Care, Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Apr 26, 2021
Start date
Sep 24, 2021
Primary completion
Oct 16, 2023
Completion
Nov 21, 2023
Results posted
May 14, 2026
Last update
May 14, 2026

Study contacts

Matthew Sloan, MD, MSc
principal investigator · Centre for Addiction and Mental Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion